ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0825

Rheum2Learn: A Randomized Trial of Virtual vs Text-Based Rheumatology Modules

Sonam Kiwalkar1, Julianna Desmarais2, Ellen Snyder3, Lisa Schroeder4, Marissa Meissner5, Noelle A. Rolle6, Sarah Donohue7, Brittany Bettendorf8, Ira Khanna9, Karen Kruzer10, Nkechi Emejuaiwe11, Ibtissam Gad12, David Leverenz13, Michael George14, Ashima Makol15, Floranne Ernste15 and Jilie Blaszczak16, 1The Vancouver Clinic, Portland, OR, 2Oregon Health and Sciences University, Portland, OR, 3UNC Rheumatology, Chapel Hill, NC, 4Geisinger, Danville, PA, 5Geisinger Medical Center, Danville, PA, 6Medical College of Georgia at Augusta University, Evans, GA, 7University of Wisconsin, Madison, WI, 8University of Iowa, Iowa City, IA, 9Mount Sinai Hospital, New York, NY, 10Assistant Professor- University of Rochester, Victor, NY, 11Cincinnati VA Medical Center, Cincinnati, OH, 12University of Michigan, Plymouth, MI, 13Duke University, Durham, NC, 14University of Pennsylvania, Philadelphia, PA, 15Mayo Clinic, Rochester, MN, 16University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2025

Keywords: education, medical, rheumatoid arthritis, Systemic lupus erythematosus (SLE), Work Force

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: Abstracts: Professional Education (0825–0830)

Session Type: Abstract Session

Session Time: 3:00PM-3:15PM

Background/Purpose: Internal medicine (IM) residents often receive limited rheumatology training, contributing to low confidence in managing rheumatologic conditions and suboptimal performance on standardized examinations. Virtual patient (VP) modules—interactive, multimedia cases simulating real-life scenarios—offer a promising alternative by promoting clinical reasoning and learner engagement. Rooted in cognitive load and multimedia theories, VP modules may offer advantages over traditional text-based learning, which often lacks interactivity and real-world complexity. While prior research has demonstrated the effectiveness of VPs compared to no intervention, evidence comparing VPs to text-based modules in graduate medical education, particularly in rheumatology, remains limited.

Methods: In a multi-site, randomized crossover study, 202 IM residents from 16 U.S. residency programs were randomized into two groups: Group A completed a VP module on systemic lupus erythematosus (SLE) and a text-based module on rheumatoid arthritis (RA), while Group B completed a VP module on RA and a text-based module on SLE. Clinical reasoning was assessed via 10-item multiple-choice pre- and post-tests. Self-reported confidence was measured using 5-point Likert-scale items. Learner perceptions were evaluated through a pre-validated survey and open-ended questions. Student’s t-tests compared change in pre- and post-test scores, self-rated confidence, and perceived module effectiveness. These abstract reports interim results from data collected between Feb’24 and Jan’25.

Results: Interim analysis indicates that both module types improved knowledge. However, VP modules led to greater gains in post-test scores compared to text-based modules in both RA and SLE; differences were statistically significant in SLE (p = 0.05) and in RA (p = 0.02) modules. (Table 1). Compared to pre-survey confidence, residents who completed VP modules reported significantly higher post-survey confidence in diagnosing, evaluating, and managing both SLE and RA (p < 0.0001; Figure 1). They also rated VP modules as significantly more effective in reinforcing diagnostic reasoning and clinical decision-making skills (p < 0.0001; Figure 2). Open-ended feedback reflected a strong learner preference for VP modules, describing them as more engaging and realistic. Key benefits included interactive dialogue, clinical decision-making prompts, and visual content. Some residents described the VP format as lengthy or repetitive, while others appreciated its alignment with real-world reasoning.

Conclusion: Preliminary findings suggest that VP modules led to greater knowledge and confidence gains compared to text-based modules and VPs were preferred by learners. These findings support integrating VP-based learning into rheumatology education, especially in settings with limited faculty or clinical exposure as they offer a scalable, engaging approach to preparing IM residents for real-world rheumatologic care. Although long-term retention and sustained confidence were not assessed, future studies will be important to determine their lasting impact.

Supporting image 1Data are presented as mean percent correct (standard deviation). P-values based on unpaired t-tests comparing Group A and Group B at each timepoint. Difference reflects the absolute change from pre- to post-test scores. *Group A – VP module on lupus (highlighted in grey) and text-based module on rheumatoid arthritis; Group B – text-based module on lupus and VP module on rheumatoid arthritis (highlighted in grey).

Supporting image 2

Supporting image 3Likert scale: 1 = strongly disagree, 2 = Disagree, 3 = Neither agree or disagree, 4 = Agree, 5 = strongly Agree.


Disclosures: S. Kiwalkar: None; J. Desmarais: None; E. Snyder: None; L. Schroeder: None; M. Meissner: None; N. Rolle: None; S. Donohue: None; B. Bettendorf: None; I. Khanna: None; K. Kruzer: None; N. Emejuaiwe: None; I. Gad: None; D. Leverenz: Pfizer, 5, Sanofi, 2, UCB, 2; M. George: Boehringer-Ingelheim, 2, GlaxoSmithKlein(GSK), 5, Janssen, 5, Pfizer, 2, 5; A. Makol: Amgen, 12, Site PI for Clinical trial, AstraZeneca, 12, Site PI for Clinical trial, Boehringer-Ingelheim, 1, 12, Site PI for Clinical trial, Sanofi Genzyme, 12, Site PI for Clinical trial; F. Ernste: Priovant Therapeutics, 5; J. Blaszczak: None.

To cite this abstract in AMA style:

Kiwalkar S, Desmarais J, Snyder E, Schroeder L, Meissner M, Rolle N, Donohue S, Bettendorf B, Khanna I, Kruzer K, Emejuaiwe N, Gad I, Leverenz D, George M, Makol A, Ernste F, Blaszczak J. Rheum2Learn: A Randomized Trial of Virtual vs Text-Based Rheumatology Modules [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/rheum2learn-a-randomized-trial-of-virtual-vs-text-based-rheumatology-modules/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheum2learn-a-randomized-trial-of-virtual-vs-text-based-rheumatology-modules/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology